Takeda, Shattuck Labs partner on immuno-oncology

Monday, August 14, 2017

Takeda Pharmaceutical and Shattuck Labs have entered into a research collaboration to explore and develop checkpoint fusion proteins that have the potential to become highly differentiated, next-generation immunotherapies. Under the terms of the collaboration agreement, Takeda will hold options for exclusive global development and commercialization rights for up to four molecules resulting from the collaboration.

[Read More]

Julian Adams joins Vedantra Pharmaceuticals as executive chairman

Thursday, January 12, 2017

Vedantra Pharmaceuticals, an immunotherapy company focused on developing products for cancer and infectious disease, has announced the appointment of Julian Adams, Ph.D., as executive chairman. Dr. Adams, who recently stepped down as president of Research and Development at Infinity Pharmaceuticals, will oversee strategic and operational responsibilities, fund raising and drive R&D program development for the company.

[Read More]

bluebird bio hires Susanna High and Andrew Obenshain

Monday, December 5, 2016

bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, has announced two new appointments as part of the company’s ongoing preparation for commercial readiness. Susanna High was named chief operating officer and Andrew Obenshain was named senior vice president and head of Europe.

[Read More]

Veristat appoints James Roach, M.D. as chief medical officer

Monday, November 7, 2016

Veristat has appointed James (Jim) Roach, M.D., FACP, FCCP as its new chief medical officer to bolster the expansion of its clinical operations, medical and regulatory affairs offerings. Dr. Roach will assume his position of chief medical officer on December 2, 2016. In this role, he will lead and grow the clinical operations, medical writing, medical monitoring, safety/pharmacovigilance and regulatory affairs teams at Veristat.

[Read More]

Renewed attention for investigator-initiated trials

Tuesday, December 15, 2015

After a five- to eight-year decline, investigator-initiated trials (IITs) are gaining renewed interest as more biopharmaceutical companies are using them as a creative and cost-effective way to innovate and further improve patient safety.

[Read More]

Third Rock Ventures expands, strengthens team

Wednesday, May 15, 2013

Third Rock Ventures, a venture capital firm focused on building healthcare companies, has expanded and strengthened its team with several appointments and role changes. These additions allow Third Rock to continue to support the launch of new companies focused on disruptive areas of science and medicine, the maturation and development of its current portfolio companies and the overall strategy and direction of the firm.

[Read More]

Parexel CEO Rickenbach to receive MassBio’s Henri Termeer Innovative Leadership Award

Monday, March 11, 2013

Josef von Rickenbach, chairman and CEO of Parexel International, a global bio/pharmaceutical services organization, will be honored for his commitment and contributions to the biotechnology industry, by the Massachusetts Biotechnology Council (MassBio), a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry.

[Read More]